UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

British journal of haematology, 2012-10, Vol.159 (2), p.154-163

2012

Volltextzugriff (PDF)

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

Clinical cancer research, 2006-08, Vol.12 (16), p.4908-4915

2006

Volltextzugriff (PDF)

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

Journal of medicinal chemistry, 2009-01, Vol.52 (2), p.278-292

2009

Volltextzugriff (PDF)

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

Cancer research (Chicago, Ill.), 2000-03, Vol.60 (5), p.1193-1196

2000

Volltextzugriff (PDF)

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (11), p.2623-2628

1999

Volltextzugriff (PDF)

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

Cancer gene therapy, 1999-11, Vol.6 (6), p.499-504

1999

Volltextzugriff (PDF)

Hyperzincuria in IDDM women. Relationship to measures of glycemic control, renal function, and tissue catabolism

Diabetes care, 1988-11, Vol.11 (10), p.780-786

1988

Volltextzugriff (PDF)

Differences in viral distribution and cell adhesion molecule expression in the intestinal tract of rhesus macaques infected with pathogenic and nonpathogenic SIV

Journal of medical primatology, 1995-05, Vol.24 (3), p.132-140

1995

Volltextzugriff (PDF)

Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques

AIDS (London), 1994-09, Vol.8 (9), p.1245-1256

1994

Volltextzugriff (PDF)

EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression

PLoS pathogens, 2016-05, Vol.12 (5), p.e1005622-e1005622

2016

Volltextzugriff (PDF)

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

British journal of haematology, 2014-06, Vol.165 (6), p.870-882

2014

Volltextzugriff (PDF)

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Clinical cancer research, 2005-05, Vol.11 (10), p.3633-3641

2005

Volltextzugriff (PDF)

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Blood, 2005-04, Vol.105 (7), p.2941-2948

2005

Volltextzugriff (PDF)

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

Nature medicine, 2000-10, Vol.6 (10), p.1134-1139

2000

Volltextzugriff (PDF)

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

Clinical cancer research, 2005-07, Vol.11 (14), p.5281-5291

2005

Volltextzugriff (PDF)

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

Clinical cancer research, 2000-03, Vol.6 (3), p.798

2000

Volltextzugriff (PDF)

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints

Cancer research (Chicago, Ill.), 2002-11, Vol.62 (21), p.6070-6079

2002

Volltextzugriff (PDF)

Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration

Clinical cancer research, 2000-12, Vol.6 (12), p.4908-4914

2000

Volltextzugriff (PDF)

Replication-selective adenoviruses as oncolytic agents

The Journal of clinical investigation, 2000-04, Vol.105 (7), p.847-851

2000

Volltextzugriff (PDF)

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

Nature medicine, 2000-08, Vol.6 (8), p.879-885

2000

Volltextzugriff (PDF)

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Nature medicine, 1997-06, Vol.3 (6), p.639-645

1997

Volltextzugriff (PDF)

An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells

Science (American Association for the Advancement of Science), 1996-10, Vol.274 (5286), p.373-376

1996

Volltextzugriff (PDF)

An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

British journal of haematology, 2014-06, Vol.165 (6), p.870-882

2014

Volltextzugriff (PDF)

The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis

Journal of experimental therapeutics & oncology, 2013, Vol.10 (3), p.219-233

2013

Volltextzugriff (PDF)

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Blood, 2012-11, Vol.120 (21), p.372-372

2012

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

Hyperzincuria in IDDM women. Relationship to measures of glycemic control, renal function, and tissue catabolism

Differences in viral distribution and cell adhesion molecule expression in the intestinal tract of rhesus macaques infected with pathogenic and nonpathogenic SIV

Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques

EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia

A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints

Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration

Replication-selective adenoviruses as oncolytic agents

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells

An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Suchergebnisse filtern